Momenta pharmaceuticals, inc. (MNTA)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Collaboration revenue

28,644

23,868

58,508

67,001

74,850

75,589

97,375

106,581

117,120

138,882

108,469

113,523

116,383

109,619

97,817

82,468

100,938

89,650

88,436

83,977

50,027

52,250

43,821

45,236

38,647

35,465

35,443

29,794

47,296

63,921

80,648

163,491

229,124

283,068

305,574

220,424

0

0

0

Operating expenses:
Research and development

150,777

144,542

134,903

119,525

118,734

124,004

131,457

138,644

146,367

149,226

139,460

133,114

127,224

119,880

131,066

131,231

132,041

126,033

114,658

110,433

102,539

106,482

112,527

112,454

108,359

103,999

93,300

86,098

84,115

80,345

80,045

76,119

70,276

64,657

55,906

51,377

0

0

0

General and administrative

140,180

149,822

112,421

112,777

88,699

85,105

79,407

79,673

79,714

82,207

20,079

15,134

7,458

0

60,674

57,375

55,808

48,051

44,803

43,447

41,337

45,164

44,887

42,761

43,058

41,057

39,584

41,606

42,443

43,682

44,022

44,503

41,355

38,710

36,320

30,799

0

0

0

Restructuring

84

110

2,449

17,965

17,833

17,807

15,535

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other operating expense

41,991

41,205

42,936

72,936

0

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain (Loss) on Termination of Lease

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

319,312

321,959

278,989

293,203

255,266

256,916

256,399

248,317

226,081

231,433

224,005

212,714

199,148

184,346

191,740

188,606

187,849

174,084

159,461

153,880

143,876

151,646

157,414

155,215

151,417

145,056

132,884

127,704

126,558

124,027

124,067

120,622

111,631

103,367

92,226

82,176

0

0

0

Operating loss

-290,668

-298,091

-220,481

-226,202

-180,416

-181,327

-159,024

-141,736

-108,961

-92,551

-115,536

-99,191

-82,765

-74,727

-93,923

-106,138

-86,911

-84,434

-71,025

-69,903

-93,849

-99,396

-113,593

-109,979

-112,770

-109,591

-97,441

-97,910

-79,262

-60,106

-43,419

42,869

117,493

179,701

213,348

138,248

0

0

0

Other income (expense):
Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

442

460

548

666

778

881

950

1,024

1,108

1,200

1,238

1,198

1,084

925

746

544

376

0

0

0

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

91

163

237

0

0

0

Other income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

280

274

248

246

239

235

233

0

0

0

-

-

-

-

-

-

-

-

-

-

Other income, net

5,901

8,036

8,881

8,845

7,143

5,266

4,967

4,791

4,993

4,455

55,220

54,519

54,015

53,724

2,217

1,926

1,463

1,121

895

722

734

796

912

1,017

1,116

1,183

1,417

1,446

1,480

1,458

1,196

1,068

875

655

381

139

0

0

0

Net loss

-284,767

-290,055

-211,600

-217,357

-173,273

-176,061

-154,057

-136,945

-103,968

-88,096

-60,316

-44,672

-28,750

-21,003

-91,706

-104,212

-85,448

-83,313

-70,130

-69,181

-93,115

-98,600

-112,681

-108,962

-111,654

-108,408

-96,024

-96,464

-77,782

-58,648

-42,223

43,937

118,368

180,356

213,729

138,387

0

0

0

Earnings Per Share [Abstract]
Basic and diluted net loss per share (in dollars per share)

-0.34

-0.85

-0.45

-1.16

-0.46

-0.07

-0.65

-0.91

-0.63

0.20

-0.44

-0.50

-0.46

0.61

-0.26

-0.31

-0.35

-0.44

-0.44

-0.04

-0.40

-0.31

-0.56

-0.51

-0.53

-0.58

-0.50

-0.57

-0.48

-0.35

-0.51

-0.20

-0.10

-

-

-

-

-

-

Basic (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.03

1.21

1.29

1.15

0.72

-0.34

Diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.02

1.18

1.26

1.13

0.70

-0.34

Weighted average shares outstanding:
Weighted average shares used in computing basic and diluted net loss per share (in shares)

117,125

101,857

98,709

98,595

98,195

82,154

77,229

76,543

75,454

74,843

74,611

73,379

69,711

69,008

68,799

68,532

68,285

68,344

68,004

61,680

54,492

52,289

51,545

51,466

51,356

51,192

51,055

50,746

50,635

50,550

50,500

50,354

50,240

-

-

-

-

-

-

Basic (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

50,134

50,034

49,708

49,532

44,719

44,069

Diluted (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

50,909

51,048

51,001

50,334

46,032

44,069

Comprehensive loss:
Comprehensive loss:
Net Income (Loss) Available to Common Stockholders, Basic

-284,767

-290,055

-211,600

-217,357

-173,273

-176,061

-154,057

-136,945

-103,968

-88,096

-60,316

-44,672

-28,750

-21,003

-91,706

-104,212

-85,448

-83,313

-70,130

-69,181

-93,115

-98,600

-112,681

-108,962

-111,654

-108,408

-96,024

-96,464

-77,782

-58,648

-42,223

43,937

118,368

180,356

213,729

0

0

0

-

Net unrealized holding gain (loss) on available-for-sale debt securities

-374

383

625

820

830

53

-211

-296

-595

-226

-203

-291

-117

82

234

266

135

20

-4

-26

-7

-41

-100

24

-37

-86

194

56

0

-

0

0

-

-

-

-

-

-

-

Comprehensive loss

-285,141

-289,672

-210,975

-216,537

-172,443

-176,008

-154,268

-137,241

-104,563

-88,322

-60,519

-44,963

-28,867

-20,921

-91,472

-103,946

-85,313

-83,293

-70,134

-69,207

-93,122

-98,641

-112,781

-108,938

-111,691

-108,494

-96,075

-96,428

-77,762

-58,456

-41,904

43,863

118,463

180,291

0

0

0

-

-

Product revenue
Collaboration revenue

25,455

19,115

21,999

30,069

38,515

39,684

42,290

39,559

46,920

66,803

69,251

81,700

83,252

74,648

76,641

61,968

60,581

48,503

35,440

31,488

17,873

19,963

20,119

20,179

16,117

16,701

22,610

20,415

38,139

54,772

70,107

152,245

216,741

270,473

288,514

0

0

0

-

Research and development revenue
Collaboration revenue

3,189

4,753

36,509

36,932

36,335

35,905

55,085

67,022

70,200

72,079

39,218

31,823

33,131

34,971

21,176

20,500

40,357

41,147

52,996

52,489

32,154

32,287

23,702

25,057

22,530

18,764

12,833

9,379

9,157

9,149

10,541

11,246

12,383

12,595

17,060

16,627

0

0

0